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Like the CCR5 chemokine receptors of humans and
rhesus macaques, the very homologous (;98–99% iden-
tical) CCR5 of African green monkeys (AGMs) avidly
binds b-chemokines and functions as a coreceptor for
simian immunodeficiency viruses. However, AGM CCR5
is a weak coreceptor for tested macrophage-tropic (R5)
isolates of human immunodeficiency virus type 1 (HIV-
1). Correspondingly, gp120 envelope glycoproteins de-
rived from R5 isolates of HIV-1 bind poorly to AGM
CCR5. We focused on a unique extracellular amino acid
substitution at the juncture of transmembrane helix 4
(TM4) and extracellular loop 2 (ECL2) (Arg for Gly at
amino acid 163 (G163R)) as the likely source of the weak
R5 gp120 binding and HIV-1 coreceptor properties of
AGM CCR5. Accordingly, a G163R mutant of human
CCR5 was severely attenuated in its ability to bind R5
gp120s and to mediate infection by R5 HIV-1 isolates.
Conversely, the R163G mutant of AGM CCR5 was sub-
stantially strengthened as a coreceptor for HIV-1 and
had improved R5 gp120 binding affinity relative to the
wild-type AGM CCR5. These substitutions at amino acid
position 163 had no effect on chemokine binding or sig-
nal transduction, suggesting the absence of structural
alterations. The 2D7 monoclonal antibody has been re-
ported to bind to ECL2 and to block HIV-1 binding and
infection. Whereas 2D7 antibody binding to CCR5 was
unaffected by the G163R mutation, it was prevented by a
conservative ECL2 substitution (K171R), shared be-
tween rhesus and AGM CCR5s. Thus, it appears that the
2D7 antibody binds to an epitope that includes Lys-171
and may block HIV-1 infection mediated by CCR5 by
occluding an HIV-1-binding site in the vicinity of Gly-
163. In summary, our results identify a site for gp120
interaction that is critical for R5 isolates of HIV-1 in the
central core of human CCR5, and we propose that this
site collaborates with a previously identified region in
the CCR5 amino terminus to enable gp120 binding and
HIV-1 infections.
Infection by human immunodeficiency virus type 1 (HIV-1)1
involves adsorption onto cell-surface CD4, followed by interac-
tion of the viral gp120zgp41 envelope glycoprotein complexes
with a coreceptor (1–6). Association of gp120 with CD4 induces
a conformational change that exposes previously buried
epitopes in gp120 and gp41 (7–9), including a site for gp120
interaction with the coreceptor (10–13). The latter interaction
is thought to cause an additional conformational change that
facilitates fusion of the viral and cellular membranes, resulting
in transfer of the viral cores into the cytosol (14). The known
coreceptors are all G protein-coupled receptors with seven
transmembrane domains (TM) that normally signal in re-
sponse to cognate chemokine ligands (15). The major coreceptor
for macrophage-tropic (R5) isolates of HIV-1 is CCR5, a recep-
tor for the b-chemokines MIP1a, MIP1b, and RANTES (1–5,
16). The coreceptor for T cell-tropic HIV-1 isolates is CXCR4, a
receptor for the a-chemokine stromal cell-derived factor (6, 17,
18). R5 isolates are generally responsible for initial infection of
individuals and predominate during the relatively early stages
of disease, whereas T cell-tropic and dual-tropic viruses accu-
mulate in the late stages of immune system demise (19–24).
Previous investigations have demonstrated that multiple ex-
tracellular regions of CCR5 may be important for infection by
R5 isolates of HIV-1 (25–31). Studies using receptor chimeras
(fusions between CCR5 and chemokine receptors unable to
support HIV-1 infection) initially highlighted the contributions
to infection of the amino-terminal region of CCR5 and extra-
cellular loops (ECLs) 1 and 2 (25–30). Residues of the amino
terminus of CCR5 critical to gp120 binding and infection
(Y10DINYY15) have since been more precisely defined by other
approaches including site-directed mutagenesis (25, 28, 32–
36), whereas a potential role of ECL2 in mediating HIV-1 viral
infectivity has been strengthened by a report by Wu and co-
workers (31) that a monoclonal antibody whose epitope maps to
a peptide derived from this domain (2D7) inhibits both infec-
tion and 125I-gp120 binding. However, it is not known if 2D7
exerts its inhibitory effects by attaching to a site on CCR5
required for HIV-1 binding or if its binding globally alters
CCR5 conformation or sterically interferes with gp120 interac-
tion with another region of the receptor. Therefore, outside of
an interaction with the amino terminus of the receptor, other
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interactions between HIV-1 and CCR5 critical to viral infection
are incompletely delineated.
Recently, we found a high frequency of heterozygosity for
CCR5 substitution polymorphisms in African green monkeys
(AGMs), a group of primate species believed to have been
infected by immunodeficiency viruses since ancient times (28).
These initially identified substitutions predominantly cluster
in the amino terminus (D13N and Y14N) and in ECL1 (Q93R
and Q93K), and they partially inhibit infections by multiple
SIVagm isolates.
2 Infectivities of R5 HIV-1 isolates were also
inhibited by the Y14N and Q93R substitutions in the context of
the wild-type AGM CCR5 and by Y14N in the context of human
CCR5 (28). However, although wild-type AGM CCR5 is a
strong coreceptor for SIV isolates, it is a relatively weak core-
ceptor for R5 HIV-1 isolates (28). This observation was surpris-
ing because rhesus macaque CCR5 is a strong coreceptor for R5
HIV-1 isolates (37) but differs from AGM CCR5 in only three
amino acids. Indeed, the only extracellular amino acid substi-
tution that is unique to AGM CCR5 and absent from rhesus
and human CCR5s is G163R, which occurs at the juncture of
TM4 and ECL2. We now describe evidence that this site is
critical for gp120 binding and for infections by all tested R5
isolates of HIV-1.
EXPERIMENTAL PROCEDURES
Cells and Viruses—HeLa and HEK293T cells were from the Ameri-
can Type Culture Collection (ATCC, Rockville, MD). HeLa-CD4 (clone
HI-J) and HeLa-CD4-CCR5 (clone JC.37) cells were described previ-
ously (38, 39). HeLa and HeLa-derived cells were maintained in Dul-
becco’s modified Eagle’s medium (DMEM) with 10% fetal bovine serum
(FBS). HEK293T cells were maintained in the same medium supple-
mented with glucose (4.5 g/liter). The SF162, JRFL, ADA, and BaL R5
isolates of HIV-1 were obtained from the AIDS Research and Reference
Reagent Program, Division of AIDS, NIAID, National Institutes of
Health. HIV-1 viruses were passaged in phytohemagglutinin-stimu-
lated human peripheral blood mononuclear cells. Medium was har-
vested at times of peak reverse transcriptase release, passed through a
0.45-mm pore size filter, aliquoted, and stored at 280 °C. The JRCSF
isolate was obtained as an infectious molecular clone, pYK-JRCSF,
from the AIDS Research and Reference Reagent Program, Division of
AIDS, NIAID, National Institutes of Health, and transfected into HeLa
cells. Culture medium was harvested after 72 h and used to infect
HeLa-CD4-CCR5 cells (clone JC.37). Viral supernatants were har-
vested and filtered as above, and the supernatant from day 3 after
infection was used in this study.
CCR5 Constructs and Mutagenesis—The rhesus macaque CCR5 ex-
pression plasmid was the generous gift of Zhiwei Chen and Preston
Marx (Aaron Diamond AIDS Research Center) (37). Constructs contain-
ing human and AGM CCR5 were previously described (28). For some
experiments, the human and AGM CCR5 plasmids were mutagenized
to create the AGM (R163G) and human (G163R) CCR5s by the Quick-
Change mutagenesis kit (Stratagene, La Jolla, CA) as directed by the
manufacturer; for the remaining experiments, mutants with identical
coding sequences were created by swapping the BclI to BglII restriction
fragment between AGM and human CCR5s. In either case, the entire
coding sequence of CCR5 was sequenced to confirm that only the de-
sired mutation was introduced. The chimeric CCR5s were created by
splicing AGM and human CCR5 at either the BclI or BglII restriction
site as described (28). The human (Y14N) site-directed mutant was
described and characterized previously (28).
gp120 Expression and Purification—The molecular clone pYU2 was
obtained from the AIDS Research and Reference Reagent Program,
Division of AIDS, NIAID, National Institutes of Health, and the molec-
ular clone SF162 was from Cecelia Chang-Meyer. The expression and
purification of YU2 gp120 are described, with similar procedures used
for expression and purification of SF162 gp120. Briefly, the YU2 enve-
lope glycoprotein gp120 was polymerase chain reaction-amplified from
proviral DNA using synthetic oligonucleotides designed according to
the published sequence. The resulting polymerase chain reaction prod-
uct was ligated into pSC11 (40), modified to contain a multilinker
sequence, to generate pJL23, and was sequence verified. The 39-anti-
sense primer design appended a FLAG (Eastman Kodak Co.) epitope to
the gp120 viral envelope protein following position Arg-498.
Plasmid pJL23 was used to generate recombinant vaccinia virus
Venv-4 using standard techniques (41) for large scale expression of
soluble gp120-FLAG. 16 T-225 flasks of CV-1 cells were seeded to
contain approximately 1–2 3 107 cells/flask on the day of infection.
Cells were infected with Venv-4 at a multiplicity of infection of 5 for 2 h
in 0.1% bovine serum albumin in phosphate-buffered saline. After in-
fection, cell monolayers were washed twice with phosphate-buffered
saline and refed with 50 ml of Opti-MEM (Life Technologies, Inc.) per
flask. After approximately 68 h, supernatants were harvested by cen-
trifugation at 6000 rpm for 30 min at 4 °C. Clarified supernatants were
supplemented with Triton X-100 (Boehringer Mannheim) to 0.5%,
quick-frozen in liquid nitrogen, and stored at 270 °C.
Soluble gp120-FLAG proteins were purified by fast protein liquid
affinity chromatography using M2-anti-FLAG affinity gel (Kodak) in an
HR5/5 column (Amersham Pharmacia Biotech, bed volume ;1 ml)
equilibrated in TBS (50 mM Tris-HCl, pH 8.0, 150 mM NaCl). Culture
supernatants (500–1000 ml) were thawed at 37 °C, supplemented to 10
mg/ml each aprotinin and leupeptin (Boehringer Mannheim), filtered
through a 0.22-mm filter, and then passed continuously over the M2
column at 1 ml/min at 4 °C for 24–28 h. The resin was washed exten-
sively with TBS, and bound proteins were eluted with 100 mM synthetic
FLAG peptide (Kodak) in TBS. Fractions (1 ml) containing gp120-FLAG
were identified by Colloidal Blue staining of 10% SDS-polyacrylamide
gel electrophoresis gels (Novex, San Diego, CA). Peak fractions were
pooled, snap-frozen in liquid nitrogen, and stored at 270 °C.
Pooled fractions were separated from synthetic FLAG peptide and
TBS by C4 reverse phase chromatography. Samples were loaded onto a
5-cm Vydac C4 analytical column at 1 ml/min in 10% acetonitrile, 0.1%
trifluoroacetic acid. Using a 25–50% gradient, gp120 eluted at approx-
imately 36–38% acetonitrile. Samples were collected on dry ice and
were immediately lyophilized. Dried samples were resuspended in
phosphate-buffered saline. Relative protein concentration determina-
tions were made using a modified gp120 capture enzyme-linked immu-
nosorbent assay (Intracel, Issaquah, WA) using anti-gp120 monoclonal
antibody A32 from James Robinson at Tulane. Fractions with peak
activity according to enzyme-linked immunosorbent assay were sub-
jected to amino acid analysis for final concentration determinations.
BaL gp120 was purified as described previously from the culture
medium of Schneider 2 Drosophila cells that were generously donated
by Dr. Raymond Sweet (SmithKline Beecham) (42).
Binding Assays—125I-MIP1a (2200 mCi/mmol) was purchased from
NEN Life Science Products. Conditions for competition binding assays
using chemokines are similar to those described previously (43).
YU2 gp120 was iodinated by the chloramine-T method according to
the procedure of Rollins et al. (44). Assay conditions for measurement of
direct binding of 125I-YU2 gp120 to CCR5-expressing cells, in the pres-
ence of 10 nM soluble CD4, and inhibition of binding of 125I-MIP1a to
CCR5-expressing cells by YU2 gp120zsCD4 complexes have also been
described previously (11).3
For gp120 binding assays done using cells expressing transmem-
brane-bound CD4, pcDNA3 expression vectors for CD4 and CCR5 were
cotransfected into HEK293T cells by the standard DEAE-dextran/chlo-
roquine method (45), except that the cells were plated in flasks that
were treated with 0.1 mg/ml poly-L-lysine (Sigma) for 30 min, and no
Me2SO shock was used. Cells were seeded 48 h after transfection at 2 3
105 cells/well in poly-L-lysine-treated 24-well tissue culture cluster
plates. 24 h later cells were incubated with the indicated concentration
of BaL gp120 in DMEM, 10% FBS for 30 min at 37 °C. 125I-MIP1b (2200
mCi/mmol, NEN Life Science Products) was added to a final concentra-
tion of 0.5 nM, and cells were incubated for an additional 30 min. The
cells were washed, solubilized in 0.1 N NaOH, and counted in a gamma
counter. Background counts were determined on vector-transfected
cells and subtracted from the values obtained on CCR5-transfected
cells. Counts were then expressed as percent binding by normalizing to
values obtained with no added gp120.
Coreceptor Activity Assays—The assay to determine infectivities by
R5 HIV-1 isolates was performed as described previously (28). Briefly,
coreceptors were transiently expressed in HeLa-CD4 (clone HI-J) cells
by the calcium phosphate transfection method (45). 48 h post-transfec-
tion the cultures were trypsinized and plated at 1.5 3 104 cells/well of
a 24-well cluster plate for HIV-1 infection. 72 h post-transfection cells
were pretreated with DEAE-dextran (8 mg/ml) at 37 °C for 20 min and
2 S. E. Kuhmann and D. Kabat, manuscript in preparation.
3 S. J. Siciliano, B. L. Daugherty, J. A. DeMartino, and M. S.
Springer, manuscript in preparation.
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then incubated with 0.2 ml of virus diluted in DMEM, 0.1% FBS at
37 °C. After 2 h the cells were fed with 1 ml of DMEM, 10% FBS, and
incubated at 37 °C for 3 days. The cells were then fixed in ethanol, and
infected foci were visualized by an immunoperoxidase assay (46), using
as primary antibody the 0.45-mm filtered supernatant from the anti-p24
hybridoma 183-H12–5C (AIDS Research and Reference Reagent Pro-
gram, Division of AIDS, NIAID, National Institutes of Health). Stained
foci were counted with a dissecting microscope under diffuse illumina-
tion, and values were normalized to those obtained using the same virus
stock in the same experiment on cells transfected with wild-type human
CCR5.
Signal Transduction—Xenopus laevis oocytes were collected and pre-
pared as described previously (47). CCR5 cDNAs were subcloned into
the oocyte expression vector pOG-1 at a site between 59- and 39-untrans-
lated Xenopus b-globin sequences. Kir 3.1 and CCR5 cRNAs were pre-
pared as described previously, and oocytes were microinjected with
5–50 ng of capped cRNA (47). Electrophysiological recording was done
by two-electrode voltage clamp 2–5 days after cRNA injection as de-
scribed (47). Briefly, the oocytes were clamped in a small chamber
continually perfused with high K1 Ringer’s solution (100 mM KCl, 2 mM
NaCl, 1.8 mM CaCl2, 1 mM MgCl2, 5 mM HEPES, pH 7.5), and recom-
binant human chemokines (Peprotech, Rocky Hill, NJ) were applied by
bath perfusion. The holding potential was set at 230 mV, and current-
voltage records were obtained during 250-ms voltage jumps to poten-
tials between 140 and 2100 mV. Desensitization kinetics were deter-
mined by least squares fit to single exponential functions.
Antibody Binding Assays—Binding of the mouse monoclonal anti-
body 2D7 was determined on HEK293T cells transfected as for gp120
binding (above). 72 h post-transfection cells were incubated with 2.5
mg/ml 2D7 (PharMingen, San Diego, CA) in DMEM, 10% FBS for 45
min at 37 °C, followed by goat anti-mouse IgG serum (Organon Teknika
Corp., Durham, NC) at a 1:400 dilution for 45 min, followed by 125I-
protein A (0.4 mCi/ml, 2 to 10 mCi/mg; NEN Life Science Products) for 45
min. The cells were then washed, solubilized in 0.1 N NaOH, and
counted in a gamma counter. Background counts were determined on
vector-transfected cells and subtracted from the values obtained on
CCR5-transfected cells. To correct for differences in CCR5 expression,
values for 2D7 binding were divided by the counts bound to duplicate
wells incubated for 1 h at 37 °C with 0.5 nM 125I-MIP1b (2200 mCi/mmol,
NEN Life Science Products).
RESULTS
Sequences of AGM, Human, and Rhesus Macaque CCR5s—
Whereas human, rhesus macaque, and chimpanzee CCR5s are
comparably able to support infection by R5 isolates of HIV-1
(28, 37, 48), AGM CCR5 is a weak HIV-1 coreceptor (28).
Experiments analyzing AGM/human CCR5 chimeras have in-
dicated that AGM residues responsible for poor coreceptor ac-
tivity map within amino acids 1–168 (28). Table I shows a
compilation of the amino acid substitutions that distinguish
CCR5s from the aforementioned primates, and Fig. 1 shows a
topological model of human CCR5 highlighting positions
among the receptors that are divergent. Strikingly, the only
amino acid substitutions unique to AGM CCR5 are G163R at
the juncture of TM4 and ECL2 and I348T in the carboxyl-
terminal cytosolic domain. Indeed, AGM and rhesus macaque
CCR5s differ in only three positions, and G163R is the only
difference in the critical region between amino acids 1 and 168.
gp120s from R5 Isolates of HIV-1 Compete Well for the Bind-
ing of MIP1a to Human and Rhesus CCR5s but Poorly for the
Binding of MIP1a to AGM CCR5—As evidenced from an anal-
ysis of the binding of 125I-MIP1a to HEK293T cells transfected
with appropriate pcDNA3-CCR5 expression vectors, human,
rhesus macaque, and AGM CCR5s were all highly expressed on
the cell surface (Fig. 2). Moreover, these CCR5s all had strong
binding affinities for human MIP1a (Fig. 2), with IC50 values,
derived using unlabeled MIP1a to displace 125I-MIP1a from
CCR5-bearing cells, of 4.8, 0.7, and 0.3 nM for human, rhesus,
and AGM, respectively.
Since we3 and others (10, 11) have previously demonstrated
that gp120 envelope glycoproteins from R5 isolates of HIV-1,
when complexed to soluble CD4, compete for the binding of
radiolabeled b-chemokines to human or rhesus CCR5, we
asked if gp120zsCD4 complexes would also inhibit the binding
of MIP1a to AGM CCR5. Surprisingly, neither complexes of
YU2 gp120zsCD4 (Fig. 3A) nor SF162 gp120zsCD4 (data not
shown) were able to displace the binding of 125I-MIP1a to AGM
CCR5-expressing cells even at concentrations of gp120 as high
as 500 nM. In contrast, the IC50 values of sCD4-complexed
gp120s in displacing MIP1a from human and rhesus receptors
was between 5 and 10 nM (Fig. 3A). The failure of 125I-MIP1a to
be displaced from AGM CCR5 in these experiments could be
explained if 125I-MIP1a and R5 gp120zsCD4 complexes bind
simultaneously but noncompetitively to AGM CCR5. Alterna-
tively, it is possible that the affinity of gp120zsCD4 for AGM
CCR5 is sufficiently low so as not to be able to displace the
radiolabeled chemokine.
To address this issue directly, we analyzed the binding of
125I-YU2 gp120zsCD4 complexes to the receptor-bearing cells.
As shown in Fig. 3B, despite the fact that cells expressing AGM
CCR5 were competent to bind 125I-MIP1a (Fig. 3A), complexes
of 125I-YU2 gp120zsCD4 bound specifically only to cells express-
ing human or rhesus CCR5s but not to cells expressing AGM
CCR5.
Role of Gly-163 in Binding and Infection of R5 Isolates of
HIV-1—The above results suggested that AGM CCR5 functions
as an attenuated coreceptor for R5 HIV-1 isolates and that it
binds with relatively poor affinity to the viral gp120 envelope
glycoproteins. To determine if the G163R substitution unique
to the extracellular surface of AGM CCR5 was responsible for
its deficits in HIV gp120 binding and coreceptor function, we
constructed and analyzed the human (G163R) and AGM
(R163G) CCR5 mutants.
Fig. 4 shows analyses of the coreceptor activities of the
wild-type and mutant CCR5s in mediating infections by five
different R5 isolates of HIV-1. Equivalent levels of surface
expression of receptor on transfected HeLa-CD4 cells were
indicated by binding of 125I-MIP1b and/or antibodies directed
against the human receptor (see Fig. 4 legend, and data not
shown). Infections were quantitated by a focal assay on HeLa-
CD4 cells transfected with the corresponding pcDNA3-CCR5
expression vectors (28) and data normalized relative to the
activity of wild-type human CCR5 in each assay. From this
figure it is clear that as compared with human CCR5, AGM
TABLE I
Sequence differences between primate CCR5s
CCR5a
Amino acid and locationb
9
NT
13
NT
49
TM1
52
TM1
78
TM2
123
ICL2
130
ICL2
163
ECL2
171
ECL2
198
ECL2
348
CT
Human I N M I F T V G K I I
Chimp D S
Rhesus T D I V L I R M
AGM T D I V L I R R T
a A blank space indicates that the sequence is identical to the reference human CCR5. The GenBank™ accession numbers for the CCR5
nucleotide sequences are as follows: human, U54994; chimpanzee, AF005663; rhesus macaque, U73739; and African green monkey, U83325.
b The abbreviations used are: NT, amino terminus; TM, transmembrane sequence; ICL, intracellular loop; ECL, extracellular loop; and CT,
carboxyl terminus.
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CCR5 is a much weaker coreceptor for all examined HIV-1
isolates. However, the AGM (R163G) substitution restores the
efficiency with which the mutant AGM receptor is able to
mediate viral infection almost to wild-type human CCR5 levels.
Reciprocally, the human (G163R) substitution reduces the co-
receptor activity of the mutant human receptor to the level of
FIG. 1. Topology of human CCR5 highlighting sites of primate sequence variations. The extracellular membrane face is above the
membrane which is indicated by solid parallel lines, whereas the intracellular face is below. The splice sites used to make CCR5 chimeras are
indicated by arrows with the names of the restriction enzymes that were employed. The highlighted amino acids are positions that differ among
the human, AGM, rhesus macaque, and chimpanzee CCR5 proteins (see Table I).
FIG. 2. Human, AGM, and rhesus CCR5s bind MIP1a with high affinity. Human (E), rhesus (M), and AGM (L) CCR5s were transiently
expressed in HEK293T cells. Affinities were determined by competition binding between a fixed concentration of 125I-MIP1a and increasing
concentrations of unlabeled MIP1a. Results are the average of triplicate determinations from a single representative experiment. 3 3 105 cells
transfected with human or rhesus CCR5 or 7.5 3 104 cells transfected with AGM CCR5 were used per determination.
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wild-type AGM CCR5.
We also analyzed the binding of b-chemokines and of YU2
and SF162 gp120zsCD4 complexes to these wild-type and mu-
tant CCR5s. As shown in Fig. 5 (C and D), the substitutions at
amino acid 163 had no significant effect on the affinities of
MIP1a for the different CCR5s. Likewise, these substitutions
had no effect on the affinities of human or AGM CCR5s for
MIP1b (see below). However, YU2 gp120zsCD4 complexes were
able to displace 125I-MIP1a much more readily from human
CCR5 than from the human CCR5 (G163R) mutant (Fig. 5A).
Similarly, YU2 gp120zsCD4 complexes displaced chemokine
more efficiently from the AGM (R163G) mutant than from
wild-type AGM CCR5 (Fig. 5B). These results suggest that the
G163R amino acid substitution found in AGM CCR5 reduces its
affinity for gp120s derived from R5 isolates of HIV-1.
We substantiated this conclusion by directly analyzing the
binding of 125I-YU2 gp120zsCD4 complexes to cell-surface
CCR5. As shown in Fig. 6, the binding of 125I-YU2 gp120zsCD4
complexes to cells transfected with human CCR5 was substan-
tially attenuated by the G163R mutation, whereas the ability
to bind to AGM CCR5 was restored by the reciprocal R163G
mutation. Results similar to those in Figs. 4 and 5 were also
obtained using gp120 derived from the R5 isolate SF162 (data
not shown).
The previous results were derived by measuring the binding
of cell-surface CCR5 to soluble complexes of monomeric gp120
and CD4. In contrast, HIV-1 infections involve cooperative
viral attachment onto cell-surface CD4 followed by interactions
with a coreceptor in the same membrane. Presumably, these
alternative pathways for gp120 interaction with CCR5 would
differ energetically, in part because the gp120 of virus adsorbed
onto cell-surface CD4 would be confined in a small space at a
FIG. 3. YU2 gp120zsCD4 complexes bind poorly to AGM CCR5. A, competition binding between unlabeled YU2 gp120zsCD4 complexes and
a fixed concentration of 125I-MIP1a to HEK293T cells expressing human (Œ), rhesus (●), or AGM (f) CCR5s. Results are the average of triplicate
determinations from a single representative experiment. 3 3 105 cells transfected with human or rhesus CCR5 or 7.5 3 104 cells transfected with
AGM CCR5 were used per determination. B, direct binding of 125I-YU2 gp120zsCD4 complexes to transiently transfected HEK293T cells expressing
human, rhesus, or AGM receptors as indicated (106 cells per determination). Results are the average of triplicate determinations from a single
representative experiment.
FIG. 4. Coreceptor activities of human, AGM, and mutant CCR5s. Relative coreceptor activities of the CCR5 constructs were determined
in HeLa-CD4 cells for each of the R5 HIV-1 isolates indicated. The coreceptor activities were normalized to the activity of human CCR5 in the same
experiment. The values are the averages of two experiments, and the error bars represent the range of values obtained. Mock-transfected cells were
transfected with pcDNA3 with no insert. The human-derived coreceptors were expressed in the HeLa-CD4 cells as indicated by binding of rabbit
anti-CCR5 serum as described previously (28). The values for binding from a representative experiment were as follows: human, 15.0 6 0.9 cpm/mg
of protein; human (G163R), 8.4 6 2.3 cpm/mg of protein; and human (Y14N), 5.0 6 1.6 cpm/mg of protein. This antiserum does not efficiently
recognize the AGM-derived CCR5s, largely due to the N13D substitution in the amino terminus (S. E. Kuhmann and D. Kabat, unpublished
observations). Likewise, these coreceptors also bound the 2D7 monoclonal antibody: human, 33.3 6 1.0 cpm/mg of protein; human (G163R), 11.6 6
0.7 cpm/mg of protein; and human (Y14N), 26.2 6 0.7 cpm/mg of protein. This antibody also does not efficiently recognize the AGM-derived CCR5s,
largely due to the K171R substitution in ECL2 (see Table III). Thus, expression of AGM derived CCR5s was inferred from binding of MIP1a and
MIP1b (see Figs. 5 and 7, and data not shown).
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relatively high concentration. For these reasons, we coex-
pressed full-length human CD4 with the CCR5s in HEK293T
cells, and we analyzed the displacement of 125I-MIP1b by
gp120 derived from an R5 HIV-1 isolate (BaL). 125I-MIP1b was
used for this analysis because it binds with equivalent affinity
to all of the CCR5s being tested, with IC50 values, derived using
unlabeled MIP1b to displace 125I-MIP1b from CCR5-bearing
cells, of 6.9 6 1.3, 3.9 6 0.8, 5.8 6 1.5, and 4.4 6 0.9 nM for
human, AGM, human (G163R), and AGM (R163G) CCR5s,
respectively (data not shown). As shown in Fig. 7, the resulting
125I-MIP1b displacement data were qualitatively similar to the
previous results obtained using YU2 or SF162 gp120zsCD4
complexes (i.e. Fig. 5, A and B). Importantly, these data cor-
roborate our original findings by demonstrating that
gp120zCD4 complexes on cell surfaces bind more avidly to hu-
man CCR5 than to the human (G163R) CCR5 mutant and more
avidly to AGM (R163G) CCR5 than to wild-type AGM CCR5.
Signal Transduction by Wild-type and Mutant AGM and
Human CCR5s—To learn further if mutations at position 163
cause major disruption of CCR5 structure or function, we quan-
titatively analyzed the signal-transducing properties of these
receptors in response to MIP1a, MIP1b, and RANTES (see
“Experimental Procedures”). As illustrated by the representa-
tive results in Fig. 8, human and AGM CCR5s were highly
responsive to b-chemokines, and the signaling was not signif-
icantly affected by the substitutions at position 163. As shown
previously, continued exposure to chemokines in this system is
followed by down-modulation of signaling responses (47). The
extents of down-modulation and the time constants for desen-
sitization of the responses were also not significantly altered by
FIG. 5. CCR5 substitutions at amino acid 163 alter the binding properties of YU2 gp120zsCD4 complexes but not MIP1a. For A and
B, YU2 gp120zsCD4 complexes were used to compete for binding of 125I-MIP1a to HEK293T cells. Results are the average of triplicate
determinations from a single representative experiment using cells transfected with human CCR5 (E) or the human (G163R) receptor mutant (M)
in A, or cells transfected with AGM CCR5 (E) or the AGM (R163G) receptor mutant (M) in B. C and D, unlabeled MIP1a competes for the binding
of 125I-MIP1a to transiently transfected HEK293T cells expressing one of four CCR5 variants. C, data are from cells transfected with human CCR5
(E) or the G163R human receptor mutant (M). D, data are from cells transfected with AGM CCR5 (E) or the AGM (R163G) receptor mutant (M).
In all cases, 105 cells were used per determination.
FIG. 6. CCR5 substitutions at amino acid 163 alter the binding
properties of 125I-YU2 gp120zsCD4 complexes. The direct binding of
125I-gp120zsCD4 complexes was measured using transiently transfected
HEK293T cells expressing human, human (G163R) mutant, AGM, or
AGM (R163G) mutant receptors as indicated. Results are the average of
triplicate determinations from a single representative experiment, us-
ing 106 cells per determination.
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the G163R mutation in human CCR5 (results not shown).
Binding of the 2D7 Monoclonal Antibody to CCR5 Extracel-
lular Loop 2—It has previously been reported that murine
monoclonal antibody, 2D7, binds to a peptide corresponding to
ECL2 of human CCR5 and neutralizes chemokine interaction
with CCR5 as well as HIV-1 infections by R5 isolates (31).
Indeed, we found that when HeLa-CD4 cells transfected with
human CCR5 were pretreated for 30 min with 2.5, 5, 12.5, and
25 mg/ml of 2D7, infections by the R5 isolate JRCSF were
inhibited by 24, 58, 77, and 93%, respectively (data not shown).
These results suggested that R5 gp120s may interact with
CCR5 ECL2. Since the G163R AGM substitution is at the
juncture of TM4 and ECL2 in CCR5, we analyzed the binding
of 2D7 antibody to wild-type and mutant human and AGM
CCR5s. We found that whereas 2D7 bound to human CCR5
expressed in HEK293T cells (Table II), it did not bind to AGM
CCR5 when expressed in these cells (Table II) or in HeLa/CD4
cells (data not shown). We also analyzed binding of 2D7 anti-
body to mutants and chimeras (see “Experimental Procedures”)
of human and AGM CCR5. The results shown in Table II
suggest that both Gly and Arg at position 163 are compatible
with binding of 2D7. For example, both human CCR5 and
human (G163R) CCR5 bound 2D7 antibody. In addition, amino
acids 1–168 of CCR5 site did not contribute to 2D7 binding as
both human CCR5 and the AGM/human CCR5 chimera spliced
at this site bound 2D7 antibody. However, a highly conserva-
tive K171R substitution present in ECL2 of both AGM and
rhesus CCR5 receptors destroyed the 2D7 epitope, as indicated
by the absence of 2D7 binding to a human/AGM chimera
spliced at position 168. Interestingly the K171R mutation does
not significantly interfere with HIV-1 infections, as this chi-
mera is an active coreceptor (data not shown). Taken together,
our results suggest that 2D7 binds to a region of ECL2 in
human CCR5 that encompasses Lys-171 and imply that the
interaction of 2D7 with this portion of ECL2 may inhibit HIV-1
interaction with a nearby site, which presumably includes or
whose conformation is influenced by Gly-163.
DISCUSSION
Importance of the Gly-163 Region of Human CCR5 for Bind-
ing and Infectivity of R5 Strains of HIV-1—In this investiga-
tion, we analyzed differences in the R5 gp120 binding affinities
and coreceptor activities of closely homologous human and
non-human primate CCR5 proteins. In particular, we found
that R5 gp120zsCD4 complexes bind well to human and rhesus
macaque but not AGM CCR5. In addition, as compared with
human CCR5, AGM CCR5 is a poor coreceptor for R5 isolates of
HIV-1 (e.g. see Fig. 4), despite the fact that these CCR5s do not
significantly differ in their coreceptor activities for SIVmac251
(28) and SIVagm isolates.
2 These observations were initially
surprising because AGM CCR5 contains only two unique amino
FIG. 7. CCR5 substitutions at amino acid 163 alter the binding
of BaL gp120 to cells coexpressing CD4 and CCR5. BaL gp120 was
used to compete for binding of 125I-MIP1b to HEK293T cells cotrans-
fected with CCR5 and CD4 expression plasmids. A, 125I-MIP1b binding
to wild-type human CCR5 (E) and human (G163R) mutant CCR5 (M) in
the presence of the indicated concentrations of BaL gp120. Each point
is the average from 9 experiments. B, 125I-MIP1b binding to wild-type
AGM CCR5 (E) and AGM (R163G) mutant CCR5 (M) in the presence of
the indicated concentrations of BaL gp120. Each point is the average
from 6 experiments. The error bars represent the S.E.
FIG. 8. Effect of substitutions at amino acid 163 on activation
of CCR5 by MIP1a. Inward currents were measured by two-electrode
voltage clamp in oocytes coexpressing CCR5 and Kir 3.1. A, activation
of human CCR5 (E) by MIP1a was compared with the corresponding
activation of human (G163R) mutant CCR5 (M). B, activation of AGM
CCR5 (E) by MIP1a was compared with AGM (R163G) mutant CCR5
(M). Inward K1 currents were measured at 280 mV during voltage
pulses in two (B) or three (A) oocytes. Error bars in A represent the S.E.
The EC50 values of activation were as follows: human, 0.74 6 0.28 nM;
human (G163R), 1.22 6 0.13 nM; AGM, 0.30 6 0.06 nM; and AGM
(R163G), 0.30 6 0.01 nM.
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acid substitutions that are absent from either of these other
CCR5 homologues (see Table I and Fig. 1), and only one of
these, G163R, is expected to occur in an extracellular domain of
the receptor where it has the potential to interact with the viral
glycoprotein. More specifically, the G163R substitution is pre-
dicted to lie at the juncture of TM4 and ECL2, a region that has
not previously been unambiguously implicated in HIV-1
infections.
By using mutant human receptors, we demonstrated that
the G163R substitution attenuates CCR5 binding to mono-
meric gp120s derived from R5 strains of HIV-1 (see Figs. 3 and
5–7) and, additionally, is primarily responsible for lessened
HIV-1 coreceptor activity (Fig. 4). Thus, the human (G163R)
CCR5 mutant binds gp120 less avidly than wild-type human
CCR5 and is a poor coreceptor. Similarly, the reciprocal
(R163G) CCR5 mutation of the AGM receptor enhances both
gp120 binding and HIV-1 coreceptor activity. The effects of
these substitutions were similar for five different R5 HIV-1
isolates and three different monomeric R5 gp120s examined,
indicating that the virus interaction affected by this substitu-
tion may be universal to R5 HIV-1 strains. Furthermore, as
measured by binding of 125I-MIP1b, 125I-MIP1a, or CCR5-spe-
cific antibodies (e.g. see Figs. 2, 3, 5, and 7), the effects of the
G163R substitution on gp120 binding and HIV-1 infection are
not the result of inhibition of surface expression of the receptor
or of a global alteration in receptor structure. Moreover, the
G163R substitution does not alter CCR5-mediated signal
transduction responses to MIP1a, MIP1b, or RANTES or the
kinetics or extents of CCR5 desensitization caused by pro-
longed exposures to MIP1a. Consequently, this substitution
does not significantly perturb the binding of b-chemokines or
the alternative CCR5 conformations involved in signal trans-
duction or in receptor down-modulation.
We conclude therefore that the core region of CCR5 including
Gly-163 is critically involved in adsorption and infection of R5
HIV-1 isolates. Although we have not yet thoroughly analyzed
this region by mutagenesis, we believe that it may overlap with
an epitope in ECL2 defined by the 2D7 mouse monoclonal
antibody that also is known to block gp120 binding and infec-
tivity of R5 HIV-1 isolates (31). Our results suggest that 2D7
antibody binding is sensitive to a K171R substitution (see
Table II), a position that is close in linear sequence to Gly-163
(see Fig. 1).
The particular mechanistic role of Gly-163 in viral interac-
tion with CCR5 and the dimensions of the region within the
receptor that it helps define remain unknown. However, as we
have preliminary evidence suggesting that G163E and G163A
human CCR5 mutants both bind R5-derived gp120s with high
affinity, it is unlikely that the small, flexible nature of glycine
at position 163 is required for effective interaction with the
HIV-1 envelope glycoprotein. Instead, glycine, alanine, or glu-
tamic acid at position 163 may all be permissive amino acids in
the context of CCR5, with each able to play an indirect role in
gp120 binding. In contrast, our data indicate that arginine at
position 163 clearly is non-permissive to gp120 binding and
HIV-1 infection. This may perhaps be due to the potentially
positively charged, electrostatic nature of this amino acid, or
alternatively to its unique ability to influence the conformation
of a critically important receptor site that may be nearby.
Further studies will be required to evaluate these possibilities.
Other Regions of Human CCR5 Are Also Essential for gp120
Binding and HIV-1 Infectivity—Although our results demon-
strate that the G163R AGM CCR5 amino acid substitution
plays a major role in inhibiting the binding of R5 gp120 glyco-
proteins to CCR5 and in impairing the ability of AGM CCR5 to
mediate infection by R5 HIV-1 isolates, our data also suggest
that other amino acid differences between human and AGM
CCR5s may play a supporting role. Thus, AGM (R163G) CCR5
is only approximately 60–80% as active as human CCR5 in
mediating HIV-1 infections (Fig. 4) and binds more weakly to
YU2 gp120zsCD4 complexes (Figs. 5 and 6). Similarly, human
(G163R) CCR5 binds YU2 gp120zsCD4 complexes much more
avidly than AGM CCR5 which also contains Arg at position 163
(Figs. 5 and 6). Residue substitutions outside of Gly-163 in
AGM CCR5 known to be inhibitory to HIV-1 infection and
gp120 binding include I9T and N13D (28). Likewise, amino
acids in the amino terminus of human CCR5, including amino
acids Y10DINYY15, have been shown to be critical for R5 gp120
binding and HIV-1 infectivity (25, 28, 32–35). Based on these
considerations, it appears that infection by R5 strains of HIV-1
likely requires binding interactions with two distinct regions of
CCR5 as follows: the amino terminus of the receptor and a
region of the receptor outside of the amino terminus that en-
compasses the Gly-163 region. Although it may be that these
two domains of CCR5 act independently in this regard, we
cannot rule out the possibility that they may cooperate to form
a single viral interaction site.
It is intriguing, however, that infections by R5 HIV-1 isolates
require interactions with both the Gly-163 and amino-terminal
regions of CCR5, because these regions have also been impli-
cated in agonist binding to related receptors (49). Indeed, it has
been proposed that agonists associate with chemokine recep-
tors by a two-step mechanism involving an initial interaction
with the amino terminus followed by a conformational change
that facilitates association with ECL2 (50). Our results are
compatible with a similar mechanism of HIV-1 binding to
CCR5.
CCR5 Coreceptor Activities Do Not Strictly Correlate with
Their Affinities for gp120s of R5 HIV-1 Isolates—Although it
has been known that gp120 binding to CCR5 is essential for
infections by R5 strains of HIV-1, it has been difficult to meas-
ure gp120 affinities for CCR5 in a physiologically relevant
manner. In part, this difficulty stems from the fact that infec-
tion involves trimeric gp120zgp41 complexes embedded in the
virion membrane that associate with CD4 and then diffuse on
cell surfaces to interact with the coreceptor (14, 38). In con-
trast, our binding assays employ purified soluble monomeric
gp120s (Figs. 3 and 5–7). While taking this caveat into consid-
eration in the interpretation of our data, our results still
strongly suggest that CCR5 coreceptor activities do not corre-
TABLE II
Binding of monoclonal antibody 2D7 to human, AGM, mutant, and chimeric CCR5s
CCR5 construct Amino-terminalresidues 1–162
Amino acid Ratio of 2D7 binding (cpm) to
MIP1b binding (cpm)163 171
Human Human G K 1.5 6 0.2
AGM AGM R R 0
Human (G163R) Human R K 0.6 6 0.1
AGM (R163G) AGM G R 0
Human/AGM (BglII) Human G R 0
AGM/human (BglII) AGM R K 0.4 6 0.1
AGM/human (BclI) AGM G K 0.6 6 0.1
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late precisely with their affinities for R5-derived monomeric
gp120s. For example, gp120zsCD4 complexes bind with higher
affinity to human (G163R) CCR5 than to AGM CCR5 (see Figs.
5A and 6), yet these CCR5s have similar coreceptor activities
(Fig. 4). Furthermore, AGM CCR5 mediates infections by R5
HIV-1 isolates 10–20% as well as human CCR5 (see Fig. 4)
despite its exceedingly poor apparent affinity for gp120zsCD4
complexes. Therefore, it appears that HIV-1 infections may be
surprisingly insensitive to factors that substantially decrease
virus affinities for CCR5. This conclusion may have profound
implications for the prospects of identifying CCR5-directed an-
tivirals, as small molecule inhibitors of the interaction between
gp120 and CCR5 which merely lower the affinity of gp120 for
CCR5 may not then be able to ultimately block viral entry.
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